New drug combo aims to fight Hard-to-Treat colorectal cancer
NCT ID NCT06992258
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether combining two drugs—fruquintinib and TAS-102—works better than fruquintinib alone for people with advanced colorectal cancer that hasn't responded to prior treatments. About 120 adults will be randomly assigned to one of the two groups. The main goal is to see if the combination delays cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fruquintinib and TAS-102 (trifluridine and tipiracil)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced colorectal cancer that has stopped responding to other therapies.
What could go wrong
This is a phase 2 trial with only 120 participants, so results are preliminary. The combination may not improve survival and could cause more side effects than the single drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Inova Schar Cancer
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mays Cancer Center at University of Texas Health at San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mount Sinai Cancer Research Program
RECRUITINGMiami Beach, Florida, 33140, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Orlando Health Cancer Institute
RECRUITINGOrlando, Florida, 32806, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rutgers Cancer Institute
RECRUITINGNew Brunswick, New Jersey, 08903, United States
Contact Email: •••••@•••••
-
UPenn Lancaster-Ann B. Barshinger Cancer Institute
RECRUITINGLancaster, Pennsylvania, 17601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale University
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••